Patents Assigned to Orbsen Therapeutics Limited
  • Patent number: 11952590
    Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
    Type: Grant
    Filed: June 5, 2023
    Date of Patent: April 9, 2024
    Assignee: Orbsen Therapeutics Limited
    Inventor: Stephen J. Elliman
  • Patent number: 11952589
    Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
    Type: Grant
    Filed: June 5, 2023
    Date of Patent: April 9, 2024
    Assignee: Orbsen Therapeutics Limited
    Inventor: Stephen J. Elliman
  • Patent number: 11926848
    Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
    Type: Grant
    Filed: September 9, 2021
    Date of Patent: March 12, 2024
    Assignee: Orbsen Therapeutics Limited
    Inventor: Stephen J. Elliman
  • Patent number: 11918687
    Abstract: Disclosed herein are compositions comprising isolated exosomes, for instance exosomes wherein at least 20% of the exosomes comprise SDC2, methods of isolation, and methods of use.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: March 5, 2024
    Assignee: ORBSEN THERAPEUTICS LIMITED
    Inventors: Stephen J. Elliman, Jack Kavanaugh, Larry Couture
  • Patent number: 11903997
    Abstract: Modulators of syndecan-2, such as an antibody to syndecan-2 that cross-links syndecan-2 on the cell surface or a syndiecan-2 polypeptide that interferes with syndecan-2 receptor binding, is used to regulate a Th17 mediated disease such as an autoimmune disease, fibrosis or cancer.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: February 20, 2024
    Assignee: Orbsen Therapeutics Limited
    Inventors: Stephen J. Elliman, Laura Rose Barkley, Jack Kavanaugh
  • Patent number: 11884936
    Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
    Type: Grant
    Filed: June 5, 2023
    Date of Patent: January 30, 2024
    Assignee: Orbsen Therapeutics Limited
    Inventor: Stephen J. Elliman
  • Patent number: 11434471
    Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
    Type: Grant
    Filed: December 1, 2021
    Date of Patent: September 6, 2022
    Assignee: Orbsen Therapeutics Limited
    Inventor: Stephen Joseph Elliman
  • Patent number: 11268067
    Abstract: Disclosed herein are methods of isolating SDC2+ stromal stem cells by expression of surface marker CD39. Also disclosed herein are stromal stem cells isolated by said methods.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: March 8, 2022
    Assignee: ORBSEN THERAPEUTICS LIMITED
    Inventors: Stephen J. Elliman, Jack Kavanaugh, Larry A. Couture, Lisa O'Flynn
  • Patent number: 11230700
    Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: January 25, 2022
    Assignee: ORBSEN THERAPEUTICS LIMITED
    Inventor: Stephen Joseph Elliman
  • Patent number: 11142747
    Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: October 12, 2021
    Assignee: Orbsen Therapeutics Limited
    Inventor: Stephen J. Elliman
  • Patent number: 11026994
    Abstract: SDC2, compositions that comprise SDC2, vectors encoding SDC2 and compounds that modulate expression of SDC2 by cells are used for treatment of mammalian, e.g. human, cells to achieve immunomodulation or for other specific therapeutic interventions. Cells are treated by combining the cells with SDC2, treating the cells with an antibody or fragment thereof that binds SDC2 or modulating expression or activity of SDC2 by the cells. Cells or tissue are derived from treated cells for therapeutic uses based on their immunomodulatory or other therapeutic properties.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: June 8, 2021
    Assignee: ORBSEN THERAPEUTICS LIMITED
    Inventor: Stephen Joseph Elliman
  • Patent number: 10920197
    Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: February 16, 2021
    Assignee: Orbsen Therapeutics Limited
    Inventor: Stephen Joseph Elliman
  • Patent number: 10907131
    Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: February 2, 2021
    Assignee: Orbsen Therapeutics Limited
    Inventor: Stephen Joseph Elliman
  • Patent number: 10251934
    Abstract: SDC2, compositions that comprise SDC2, vectors encoding SDC2 and compounds that modulate expression of SDC2 by cells are used for treatment of mammalian, e.g. human, cells to achieve immunomodulation or for other specific therapeutic interventions. Cells are treated by combining the cells with SDC2, treating the cells with an antibody or fragment thereof that binds SDC2 or modulating expression or activity of SDC2 by the cells. Cells or tissue are derived from treated cells for therapeutic uses based on their immunomodulatory or other therapeutic properties.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: April 9, 2019
    Assignee: Orbsen Therapeutics Limited
    Inventor: Stephen Joseph Elliman
  • Patent number: 10124038
    Abstract: Modulators of syndecan-2, such as an antibody to syndecan-2 that cross-links syndecan-2 on the cell surface or a syndecan-2 polypeptide that interferes with syndecan-2 receptor binding, is used to regulate a Th17 mediated disease such as an autoimmune disease, fibrosis or cancer.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: November 13, 2018
    Assignee: ORBSEN THERAPEUTICS LIMITED
    Inventors: Stephen J. Elliman, Laura Rose Barkley, Jack Kavanaugh
  • Publication number: 20160058832
    Abstract: SDC2, compositions that comprise SDC2, vectors encoding SDC2 and compounds that modulate expression of SDC2 by cells are used for treatment of mammalian, e.g. human, cells to achieve immunomodulation or for other specific therapeutic interventions. Cells are treated by combining the cells with SDC2, treating the cells with an antibody or fragment thereof that binds SDC2 or modulating expression or activity of SDC2 by the cells. Cells or tissue are derived from treated cells for therapeutic uses based on their immunomodulatory or other therapeutic properties.
    Type: Application
    Filed: April 16, 2014
    Publication date: March 3, 2016
    Applicant: Orbsen Therapeutics Limited
    Inventor: Stephen Joseph ELLIMAN
  • Publication number: 20150037292
    Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
    Type: Application
    Filed: February 11, 2013
    Publication date: February 5, 2015
    Applicant: Orbsen Therapeutics Limited
    Inventor: Stephen Joseph Elliman